|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu C, Geng X, Wan S, Hou H, Yu F, Jia B
and Wang L: Cecropin-P17, an analog of Cecropin B, inhibits human
hepatocellular carcinoma cell HepG-2 proliferation via regulation
of ROS, Caspase, Bax, and Bcl-2. J Pept Sci. 21:661–668. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McMillin DW and Mitsiades CS:
High-throughput approaches to discover novel immunomodulat
immunomodulatory agents for cancer. Oncoimmunology. 1:1406–1408.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurtin SE and Bilotti E: Novel agents for
the treatment of multiple myeloma: Proteasome inhibitors and
immunomodulatory agents. J Adv Pract Oncol. 4:307–321.
2013.PubMed/NCBI
|
|
5
|
Fletcher JE and Jiang MS: Possible
mechanisms of action of cobra snake venom cardiotoxins and bee
venom melittin. Toxicon. 31:669–695. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bechinger B: Structure and functions of
channel-forming peptides: Magainins, cecropins, melittin and
alamethicin. J Membr Biol. 156:197–211. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raghuraman H and Chattopadhyay A:
Melittin: A membrane-active peptide with diverse functions. Biosci
Rep. 27:189–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi JH, Jang AY, Lin S, Lim S, Kim D,
Park K, Han SM, Yeo JH and Seo HS: Melittin, a honeybee
venom-derived antimicrobial peptide, may target
methicillin-resistant Staphylococcus aureus. Mol Med Rep.
12:6483–6490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu X, Zhao B, Cheng Y, Yang Y, Huang C,
Meng X, Wu B, Zhang L, Lv X and Li J: Melittin induces PTCH1
expression by down-regulating MeCP2 in human hepatocellular
carcinoma SMMC-7721 cells. Toxicol Appl Pharmacol. 288:74–83. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang C, Chen T, Zhang N, Yang M, Li B, Lü
X, Cao X and Ling C: Melittin, a major component of bee venom,
sensitizes human hepatocellular carcinoma cells to tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha
kinase-NFkappaB. J Biol Chem. 284:3804–3813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee J and Lee DG: Melittin triggers
apoptosis in Candida albicans through the reactive oxygen
species-mediated mitochondria/caspase-dependent pathway. FEMS
Microbiol Lett. 355:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oršolić N: Bee venom in cancer therapy.
Cancer Metastasis Rev. 31:173–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dezfuli HT, Shahbazzadeh D, Eidi A,
Bagheri KP, Pakravan N, Amini S, Aghasadeghi MR and Mahdavi M:
Induction of IFN-γ cytokine response against hepatitis B surface
antigen using melittin. Gastroenterol Hepatol Bed Bench. 7:108–117.
2014.PubMed/NCBI
|
|
14
|
Antopolsky M, Azhayeva E, Tengvall U and
Azhayev A: Towards a general method for the stepwise solid-phase
synthesis of peptide-oligonucleotide conjugates. Tetrahedron Lett.
43:527–530. 2002. View Article : Google Scholar
|
|
15
|
Tu J, Wu G, Zuo Y, Zhao L and Wang S:
ZL-2, a cathelicidin-derived antimicrobial peptide, has a broad
antimicrobial activity against gram-positive bacteria and
gram-negative bacteria in vitro and in vivo. Arch Pharm Res.
38:1802–1809. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harakeh S, Azar R, Azhar E, Damanhouri GA,
Assidi M, Abu-Elmagd M, Alqahtani MH, Kumosani T, Niedzwiecki A,
Rath M, et al: Pecific nutrient combination effects on tax, NF-κB
and MMP-9 in human T-cell lymphotropic virus-1 positive malignant
T-lymphocytes. BMC Cancer. 15 Suppl 1:S22015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li C, Wu X, Zhang H, Yang G, Hao M, Sheng
S, Sun Y, Long J, Hu C, Sun X, et al: A Huaier polysaccharide
inhibits hepatocellular carcinoma growth and metastasis. Tumour
Biol. 36:1739–1745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang XY, Qiao H, Ni JM, Shi YB and Qiang
Y: Preparation of isoliquiritigenin-loaded nanostructured lipid
carrier and the in vivo evaluation in tumor-bearing mice. Eur J
Pharm Sci. 49:411–422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huo L, Yao H, Wang X, Wong GW, Kung HF and
Lin MC: Inhibition of melanoma growth by subcutaneous
administration of hTERTC27 viral cocktail in C57BL/6 mice. PLoS
One. 5:e127052010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheng M, Zhao Y, Zhang A, Wang L and Zhang
G: The effect of LfcinB9 on human ovarian cancer cell SK-OV-3 is
mediated by inducing apoptosis. J Pept Sci. 20:803–810. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Daniel D and Crawford J: Myelotoxicity
from chemotherapy. Semin Oncol. 33:74–85. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang W, Liu H, Ma L, Wang M, Wei S, Sun P,
Jiang M, Guo M, Zhou C and Dou J: Effective antimicrobial activity
of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria
based on its unnatural amino acids. Eur J Pharm Sci. 105:169–177.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou Z, Yu X, Zhang J, Tian Z and Zhang C:
TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell
anti-tumor effects in hepatocellular carcinoma. Cancer Lett.
369:298–306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McDowell KA, Hank JA, DeSantes KB,
Capitini CM, Otto M and Sondel PM: NK cell-based immunotherapies in
pediatric oncology. J Pediatr Hematol Oncol. 37:79–93. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woo SR, Corrales L and Gajewski TF: Innate
immune recognition of cancer. Annu Rev Immunol. 33:445–474. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ke M, Wang H, Zhang M, Tian Y, Wang Y, Li
B, Yu J, Dou J, Xi T and Zhou C: The anti-lung cancer activity of
SEP is mediated by the activation and cytotoxicity of NK cells via
TLR2/4 in vivo. Biochem Pharmacol. 89:119–130. 2015. View Article : Google Scholar
|
|
27
|
Schoenborn JR and Wilson CB: Regulation of
Interferon-gamma during innate and adaptive immune responses. Adv
Immunol. 96:41–101. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Balachandran S and Adams GP:
Interferon-γ-induced necrosis: An antitumor biotherapeutic
perspective. J Interferon Cytokine Res. 33:171–180. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
García-Cuesta EM, López-Cobo S,
Álvarez-Maestro M, Esteso G, Romera-Cárdenas G, Rey M, Cassady-Cain
RL, Linares A, Valés-Gómez A, Reyburn HT, et al: NKG2D is a key
receptor for recognition of bladder cancer cells by IL-2-activated
NK cells and BCG promotes NK cell activation. Front Immunol.
6:2842015.PubMed/NCBI
|
